PMID- 21375342
OWN - NLM
STAT- MEDLINE
DCOM- 20110801
LR  - 20211020
IS  - 1936-086X (Electronic)
IS  - 1936-0851 (Print)
IS  - 1936-0851 (Linking)
VI  - 5
IP  - 3
DP  - 2011 Mar 22
TI  - Nanoparticles targeting dendritic cell surface molecules effectively block T cell 
      conjugation and shift response.
PG  - 1693-702
LID - 10.1021/nn102159g [doi]
AB  - Dendritic cells (DCs) are potent professional antigen presenting cells (APC) that 
      activate naive T cells. Interaction of ICAM-1 and LFA-1 molecules on each cell is 
      required for T cell conjugation to DCs, which leads to naive CD4+ T cell 
      activation and proliferation. Nanoparticles capable of blocking LFA-1/ICAM-1 
      interaction were studied as inhibitors of T cell conjugation to DCs. Primary DCs 
      were primed with ovalbumin, then treated with a peptide that binds ICAM-1 (LABL), 
      a peptide that binds LFA-1 (cIBR), or the same peptides covalently linked to the 
      surface of poly(dl-lactic-co-glycolic acid) nanoparticles (NPs). LABL-NPs and 
      cIBR-NPs rapidly bound to DCs and inhibited T cell conjugation to DCs to a 
      greater extent than the free peptides, unconjugated nanoparticles (NPs), 
      anti-ICAM-1 antibodies, and anti-LFA-1 antibodies. In addition, DCs treated with 
      NPs or with cIBR-NPs stimulated the proliferation of T cells, but DCs treated 
      with LABL-NPs did not stimulate T cell proliferation. Nanoparticles targeting 
      ICAM-1 or LFA-1 also altered cytokine production by DC cocultured with T cells 
      when compared to free ligands, suggesting that these NPs may offer a unique tool 
      for shaping T cell response.
FAU - Chittasupho, Chuda
AU  - Chittasupho C
AD  - Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 
      66047, United States.
FAU - Shannon, Laura
AU  - Shannon L
FAU - Siahaan, Teruna J
AU  - Siahaan TJ
FAU - Vines, Charlotte M
AU  - Vines CM
FAU - Berkland, Cory
AU  - Berkland C
LA  - eng
GR  - T32 GM08359-11/GM/NIGMS NIH HHS/United States
GR  - R56 AI091996/AI/NIAID NIH HHS/United States
GR  - T32 GM008359/GM/NIGMS NIH HHS/United States
GR  - R56-AI063002/AI/NIAID NIH HHS/United States
GR  - R56 AI063002/AI/NIAID NIH HHS/United States
GR  - R03 AR054035/AR/NIAMS NIH HHS/United States
GR  - K22AI060815/AI/NIAID NIH HHS/United States
GR  - R01 AI063002/AI/NIAID NIH HHS/United States
GR  - R01-AI063002/AI/NIAID NIH HHS/United States
GR  - P20 RR016443/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20110304
PL  - United States
TA  - ACS Nano
JT  - ACS nano
JID - 101313589
RN  - 0 (Membrane Proteins)
SB  - IM
MH  - Cells, Cultured
MH  - Dendritic Cells/cytology/drug effects/*physiology
MH  - Drug Delivery Systems/methods
MH  - Humans
MH  - Membrane Proteins/*metabolism
MH  - Nanostructures/*administration & dosage
MH  - T-Lymphocytes/cytology/drug effects/physiology
PMC - PMC4207654
MID - NIHMS633857
EDAT- 2011/03/08 06:00
MHDA- 2011/08/02 06:00
PMCR- 2014/10/23
CRDT- 2011/03/08 06:00
PHST- 2011/03/08 06:00 [entrez]
PHST- 2011/03/08 06:00 [pubmed]
PHST- 2011/08/02 06:00 [medline]
PHST- 2014/10/23 00:00 [pmc-release]
AID - 10.1021/nn102159g [doi]
PST - ppublish
SO  - ACS Nano. 2011 Mar 22;5(3):1693-702. doi: 10.1021/nn102159g. Epub 2011 Mar 4.